Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma

Area of Science:

• Oncology
• Molecular Biology

Background:

• Pleural mesothelioma (PM) is a rare, aggressive cancer with limited treatment options.
• Current standard care involves chemotherapy, VEGF inhibition, and immunotherapy, but lacks targeted therapies.
• There is a critical need for validated diagnostic and prognostic biomarkers in PM.

Purpose of the Study:

• To review emerging diagnostic and prognostic biomarkers for pleural mesothelioma.
• To discuss potentially targetable molecular alterations in PM.
• To examine ongoing clinical trials for targeted therapies in PM.

Main Methods:

• Literature review of recent research on molecular alterations in PM.
• Analysis of diagnostic and prognostic biomarker studies.
• Summary of targeted therapy trials for PM.

Main Results:

• Emerging biomarkers show promise for PM diagnosis and prognosis.
• Several molecular alterations in PM are potential therapeutic targets.
• Numerous clinical trials are investigating targeted treatments for PM.

Conclusions:

• Advances in understanding PM molecular alterations are paving the way for targeted therapies.
• Biomarker discovery is crucial for improving PM patient outcomes.
• Ongoing trials offer hope for new treatment strategies in PM.